The present invention relates to a pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), which comprises granules that comprise at least therapeutic compound of formula (I) (see below), particularly 2-Methyl-2-[4-(3-methyl-2-oxo-8- quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing. The present invention also relates to processes for making such pharmaceutical compositions a kit comprising such pharmaceutical composition and the instructions provide that the pharmaceutical composition may be taken immediately to about thirty minutes after the consumption of food and related uses and methods of treatment.La présente invention concerne une composition pharmaceutique pour ladministration orale dun composé thérapeutique de formule (I), qui comprend les éléments suivants : des granules comportant au moins un composé thérapeutique de formule (I) (voir ci-dessous), en particulier 2-méthyl-2-[4-(3-méthyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phényl]-propionitrile ou 8-(6-méthoxy-pyridin-3-yl)-3-méthyl-1-(4-pipérazin-1-yl-3-trifluorométhyl-phényl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, ou son tautomère, ou son sel pharmaceutiquement acceptable, ou son hydrate ou son solvate au moins un tensioactif non ionique qui est de la vitamine E-TPGS, dans une quantité représentant environ 15 à environ 80 % en poids de la composition et au moins un agent damélioration de la dissolution sélectionné parmi le
